Overview

Islet Transplantation for Type 1 Diabetes

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the islet cell transplantation procedures and results from a previous study in Edmonton, Canada, can be repeated. The study also is designed to learn more about diabetes control using islet cell transplantation. This is a Phase I/II study (a study that examines effectiveness and looks for side effects). The transplanting of islet cells has been studied in Type 1 diabetic patients whose blood sugar levels will not stay normal, despite intensive insulin therapy. A recent study conducted in Edmonton, Canada, was able to demonstrate that islet transplantation led to insulin independence in a majority of the patients treated. This study extends the results obtained from the Edmonton study, which used islet transplantation in Type 1 diabetic patients with steroid-free immunosuppression.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Immune Tolerance Network (ITN)
Treatments:
Daclizumab
Ganciclovir
Ganciclovir triphosphate
Pentamidine
Sirolimus
Sulfamethoxazole
Tacrolimus
Trimethoprim